- $74.50m
- $67.60m
- $0.13m
Predictive Oncology Inc reports results for the quarter ended December 31 - Earnings Summary
Predictive Oncology Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Renovaro Completes First Milestone Payment To Finalize Definitive Agreement With Predictive Oncology
Brief: Predictive Oncology Moves To Finalize Definitive Merger Agreement With Renovaro Biosciences
Brief: Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
Renovaro, Predictive Oncology soar after announcing merger plans
Brief: Predictive Oncology Announces Agreement To Be Acquired By Renovaro
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Predictive Oncology Inc reports results for the quarter ended September 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Rivian, Amgen, Cava
Predictive Oncology rises on exploring strategic alternatives
Brief: Predictive Oncology Reports Quarterly Loss of $0.48 Per Share
Brief: Predictive Oncology Reports Q3 2024 Financial Results And Provides Strategic Update
Predictive Oncology Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Predictive Oncology Expands The Application Of Its Live-Cell Tumor Platform
Brief: Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Brief: Predictive Oncology CEO To Present At The Bio International Convention 2024